Citius Pharma Raises $5M via 5.08M Share Offering at $0.985
Citius Pharmaceuticals closed a $5 million gross registered direct offering selling 5,076,143 shares at $0.985 each and concurrently issued unregistered warrants for 5,076,143 shares exercisable at $0.86. Net proceeds will fund the commercial launch of LYMPHIR™, development of pipeline candidates including Mino-Lok® and CITI-002, and general corporate purposes.
1. Financing Details
Citius Pharmaceuticals executed a registered direct at-the-market offering, selling 5,076,143 shares at $0.985 per share for aggregate gross proceeds of approximately $5 million. In a concurrent private placement, it issued unregistered warrants for an equal number of shares exercisable at $0.86 per share with a five-year term.
2. Use of Proceeds
The company plans to allocate net proceeds to support the commercial launch of LYMPHIR™, cover milestone and regulatory payments, advance its Mino-Lok® catheter lock solution and CITI-002 hemorrhoid treatment programs, and for general corporate purposes.
3. Dilutive Impact
The share and warrant issuance will increase the company’s share count, with pre-funded warrants convertible into common stock and unregistered warrants exercisable at $0.86 per share over a five-year period.
4. Pipeline Context
Citius Pharma holds a 71% stake in Citius Oncology, which launched LYMPHIR for relapsed or refractory Stage I–III CTCL in December 2025, and its late-stage pipeline includes Mino-Lok®, which met primary and secondary endpoints in a Phase 3 trial, and CITI-002 (Halo-Lido), which completed a Phase 2b trial.